Imperial and Longbow support BioCeramic

Imperial Innovations and Longbow Capital had led a £1.2m funding of London-based developer of bioactive materials for orthopaedic and dental applications, BioCeramic.

The deal takes Imperial Innovations’s stake up to 36.7%, investing £300,000 to take its total investment up to £769,000.

New investor Longbow Capital invested £400,000. Longbow is a UK VC targeting the healthcare, well-being and life science sectors.

Existing investors Comvest Limited and the Esmee Fairbairn Foundation returned for the round, with Mark Rowan, a director of Imperial Innovations and a director of, and existing shareholder in, BioCeramic Therapeutics, investing a further £20,000 in the round.